文章摘要
王宏扬,陈江鹏,顾瑶华,芦臣书,夏雨,连志荣,吴正宇.药物临床研究阶段申办者和生产场地变更研究二:欧盟药物临床试验及临床试验期间变更管理要求对我国完善监管体系的启示[J].中国药事,2024,38(5):499-507
药物临床研究阶段申办者和生产场地变更研究二:欧盟药物临床试验及临床试验期间变更管理要求对我国完善监管体系的启示
Research Ⅱ on the Changes of Sponsors and Production Sites during the ClinicalResearch Phase of Drugs: The Enlightenment of EU Requirements for DrugClinical Trials and Change Management during Clinical Trials on ImprovingChina's Regulatory System
投稿时间:2023-12-11  
DOI:10.16153/j.1002-7777.2024.05.002
中文关键词: 临床试验  变更管理  申办者变更  生产场地变更  药品监管
英文关键词: clinical trial  change management  sponsor change  production site change  drug administration
基金项目:中国药品监督管理研究会委托亦弘商学院开展的“我国临床研究阶段申办者和生产场地变更研究”课题(编号 2021-Y-Y-22)
作者单位
王宏扬 阿斯利康全球研发中国中心北京 100176 
陈江鹏 沈阳药科大学亦弘商学院北京 100055 
顾瑶华 苏州工业园区药品管理中心苏州 215127 
芦臣书 百济神州(北京)生物科技有限公司北京 100022 
夏雨 扬子江药业集团上海海路生物技术有限公司上海 201203 
连志荣 阿斯利康全球研发中国中心北京 100176 
吴正宇 诺和诺德(上海)医药贸易有限公司上海 200131 
摘要点击次数: 310
全文下载次数: 208
中文摘要:
      目的:通过法规比较研究分析,为完善我国药物临床试验及临床试验期间变更管理,特别是临床试验期间申办者变更、生产场地变更及其变更管理提供参考。方法:对欧盟药物临床试验申请及临床试验期间变更管理的法规监管要求和实施情况进行研究整理,与我国当前相关监管法规建设和实施现状进行比较分析并提出建议。结果与结论:欧盟允许临床试验申办者和临床试验药物生产场地分属境内、外的临床试验注册申请及变更申请。欧盟临床试验管理制度相对成熟完善,比如其统一的临床试验申请门户网站及临床试验信息数据库、一体化的科学和伦理双重审查并行的审评程序,对申办者及其法定代理人的资质和责任要求、对临床研究用药品生产场地及其变更的监管和风险控制等监管措施,对我国有参考价值。
英文摘要:
      Objective: To provide reference through comparative research and analysis of regulations,for improving China's drug clinical trials and change management during clinical trials, especially for thesponsor change or production site change, and their change management during clinical trials. Methods: Theregulatory requirements and implementation of European Union(EU) drug clinical trial applications and changemanagement during clinical trials were collected and studied. Suggestions were provided by comparing themwith the present regulatory framework and situation of China. Results and Conclusion: In EU, the clinical trialsponsors and clinical trial drug production sites are allowed to apply for registration and change of clinical trialsboth domestically and internationally. The EU clinical trial regulatory system is relatively mature and completewhich are of reference value to China, such as a unifi ed clinical trial application portal website and clinical trialinformation database, an integrated system of scientifi c and ethical in parallel review procedures, the qualifi cationand responsibility for the sponsors and their legally designated representatives, and measures of supervision andrisk control for production sites of investigational drugs as well as their changes.
查看全文   查看/发表评论  下载PDF阅读器
关闭